Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-20 · accession 0001683607-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-24 | 2025-11-20 | REGN | Bassler Bonnie L | Dir | S - Sale+OE | $750.00 | -760 | 1,548 | -33% | -$570.0K |
| D | 2025-11-24 | 2025-11-20 | REGN | Bassler Bonnie L | Dir | M - OptEx | $371.40 | +760 | 2,308 | +49% | +$282.3K |
| D | 2025-11-24 | 2025-11-20 | REGN | Bassler Bonnie L | Dir | M - OptEx | $0.00 | -760 | 756 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | S | D | 760 | $750.00 | 1,548 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-20 | M | A | 760 | $371.40 | 2,308 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-20 | M | D | 760 | $0.00 | 756 | D | $371.40 · — to 2029-01-02 | 760 Common Stock | (F2) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |